<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00795327</url>
  </required_header>
  <id_info>
    <org_study_id>POLYL_L_02508</org_study_id>
    <nct_id>NCT00795327</nct_id>
  </id_info>
  <brief_title>Injectable POLY-L-Lactic Acid for Treatment of Hill and Valley Acne Scarring</brief_title>
  <official_title>The Canadian Study of the Use of Injectable Poly-L-Lactic Acid Dermal Implant for the Treatment of Hill and Valley Acne Scarring</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bausch Health Americas, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bausch Health Americas, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary:&#xD;
&#xD;
      Evaluate the degree of correction attainable with Poly-L-Lactic Acid(Sculptra) for the&#xD;
      correction of hill and valley acne scarring&#xD;
&#xD;
      Secondary:&#xD;
&#xD;
      Document types and incidence of device adverse events with Poly-L-Lactic Acid(Sculptra)&#xD;
      therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Physician Scar Improvement Scale (PSIS)</measure>
    <time_frame>At each visit</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Self-Assessed Scar Improvement Scale (SASIS).</measure>
    <time_frame>At each visit</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Degree of subject satisfaction with treatment</measure>
    <time_frame>At each Visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>At each visit</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single arm study</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sculptra (Poly-L-Lactic Acid Dermal Implant)</intervention_name>
    <description>Drug Device study</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Outpatient seeking therapy for correction of hill and valley acne scarring.&#xD;
&#xD;
          -  Ability and willingness to understand and comply with requirements of the trial&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The subject has active acne or chronic skin disease, inflammation or related&#xD;
             conditions, such as infection, psoriasis and herpes zoster&#xD;
&#xD;
          -  History of presence of keloid formation or hypertrophic scars&#xD;
&#xD;
          -  History of procedures that precipitate an active dermal inflammatory or hyperplastic&#xD;
             response (i.e., epilation or radiofrequency laser and chemical peeling procedures)&#xD;
             within one month of study entry&#xD;
&#xD;
          -  History of use of facial tissue augmenting therapy or aesthetic facial surgical&#xD;
             therapy within six months prior to study entry&#xD;
&#xD;
          -  Concomitant anticoagulant therapy, antiplatelet therapy or has any bleeding disorders&#xD;
&#xD;
          -  History of unanticipated adverse reactions when treated with hyaluronic acid based&#xD;
             products&#xD;
&#xD;
          -  Any condition which in the opinion of the investigator makes the patient unable to&#xD;
             complete the study per protocol (e.g., patients not likely to avoid other facial&#xD;
             cosmetic treatments; patients not likely to stay in the study for its duration because&#xD;
             of other commitments, concomitant conditions, or past history; patients anticipated to&#xD;
             be unreliable, or patients who have a concomitant condition that may develop symptoms&#xD;
             that might confuse or confound study treatments or assessments)&#xD;
&#xD;
          -  History of or current cancerous or pre-cancerous lesions in the area to be treated&#xD;
&#xD;
          -  Use of any investigational drugs or any other medical devices within 30 days of&#xD;
             enrolment&#xD;
&#xD;
          -  Use of any prohibited medication within a proscribed time period before entry&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Recent use of Accutane (patient should not be on Accutane for the last 6 months)&#xD;
&#xD;
          -  History of allergic/anaphylactic reactions, including hypersensitivity to local&#xD;
             anaesthetics (lidocaine)&#xD;
&#xD;
          -  Recent history of trauma in the face (less that 1 year)&#xD;
&#xD;
          -  Previous of Dermalive or Dermadeep&#xD;
&#xD;
        The above information is not intended to contain all considerations relevant to a patient's&#xD;
        potential participation in a clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mary Tzortzis</last_name>
    <role>Study Chair</role>
    <affiliation>Sanofi-Aventis Canada Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Laval</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 20, 2008</study_first_submitted>
  <study_first_submitted_qc>November 20, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2008</study_first_posted>
  <last_update_submitted>November 18, 2019</last_update_submitted>
  <last_update_submitted_qc>November 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

